Skip to content Skip to menu

Patients set to gain from PBAC transparency

Wednesday, 24 September 2008

Media Release

Medicines Australia chief executive Ian Chalmers has congratulated the Government on its decision to publish the Pharmaceutical Benefits Advisory Committee’s agenda six weeks in advance of its quarterly meetings.

Mr Chalmers said the measure was an important step in improving the transparency and accountability of the Pharmaceutical Benefits Scheme listing process for new medicines.

“I commend the Minister for Health and Ageing, Nicola Roxon on this important initiative, which is a significant reform to the PBS,” Mr Chalmers said.

“This measure will give patients, doctors and the wider community the opportunity to provide input to the PBAC decision-making process. They can now participate in decisions that will affect their day-to-day life.”

The move to make PBAC agendas available to the public stems from discussions held at the Medicines Australia / Department of Health and Ageing Joint Medicines Policy Conference in 2006.

It is also a result of subsequent work undertaken by the joint industry-Government Access to Medicines Working Group, which was established as a key part of PBS reform to investigate means of improving the process for listing new medicines on the PBS.

“This initiative shows what can be achieved when government and industry work in partnership to deliver improvements to the PBS,” Mr Chalmers said.

“PBS reform sought to provide a better system for Australian patients and this measure is a part of that ongoing improvement.”

The PBAC is the independent body which recommends to the Minister for Health and Ageing which medicines should be subsidised by the Australian Government on the PBS.

–ENDS–

Contact Person:

Jamie Nicholson
Media Communications Manager
Phone: 0419 220 293
Email:
Jamie.Nicholson@medicinesaustralia.com.au

Information

As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at medicinesaustralia.com.au/covid-19/

Top